BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22227650)

  • 1. Next-generation proteasome blockers promise safer cancer therapy.
    Mullard A
    Nat Med; 2012 Jan; 18(1):7. PubMed ID: 22227650
    [No Abstract]   [Full Text] [Related]  

  • 2. Proteasome Inhibitors as a Potential Cause of Heart Failure.
    Koulaouzidis G; Lyon AR
    Heart Fail Clin; 2017 Apr; 13(2):289-295. PubMed ID: 28279415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation proteasome inhibitors for cancer therapy.
    Park JE; Miller Z; Jun Y; Lee W; Kim KB
    Transl Res; 2018 Aug; 198():1-16. PubMed ID: 29654740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice.
    Fogli S; Galimberti S; Gori V; Del Re M; Danesi R
    Pharmacol Res; 2021 May; 167():105537. PubMed ID: 33684510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple myeloma--translation of trial results into reality.
    Moreau P; Rajkumar SV
    Lancet; 2016 Jul; 388(10040):111-3. PubMed ID: 27411865
    [No Abstract]   [Full Text] [Related]  

  • 6. Proteasome inhibitors: structure and function.
    Nunes AT; Annunziata CM
    Semin Oncol; 2017 Dec; 44(6):377-380. PubMed ID: 29935898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibitors for the treatment of multiple myeloma.
    Scalzulli E; Grammatico S; Vozella F; Petrucci MT
    Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
    Salvini M; Bonello F; Boccadoro M; Larocca A
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
    Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
    Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular targeting agents for multiple myeloma].
    Fujii S; Abe M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
    [No Abstract]   [Full Text] [Related]  

  • 11. Ixazomib in the management of relapsed multiple myeloma.
    Touzeau C; Moreau P
    Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Gastrointestinal Toxicities From Ixazomib: Tips to Curb Nausea, Vomiting, Diarrhea, and Constipation.
    Hall KH
    Oncology (Williston Park); 2019 Mar; 33(3):89-90. PubMed ID: 30866030
    [No Abstract]   [Full Text] [Related]  

  • 13. Three new drugs for multiple myeloma.
    Med Lett Drugs Ther; 2016 May; 58(1495):e70-1. PubMed ID: 27192621
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of proteasome inhibitors in oncology and autoimmune diseases.
    Bennett MK; Kirk CJ
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):616-25. PubMed ID: 18729013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs: More shots on target.
    Appel A
    Nature; 2011 Dec; 480(7377):S40-2. PubMed ID: 22169800
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical and marketed proteasome inhibitors for cancer treatment.
    Zhang J; Wu P; Hu Y
    Curr Med Chem; 2013; 20(20):2537-51. PubMed ID: 23531219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
    Mitsiades CS
    J Clin Oncol; 2015 Mar; 33(7):782-5. PubMed ID: 25605842
    [No Abstract]   [Full Text] [Related]  

  • 18. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
    Ri M
    Rinsho Ketsueki; 2018; 59(10):2162-2168. PubMed ID: 30305522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitor-induced gastrointestinal toxicity.
    Stansborough RL; Gibson RJ
    Curr Opin Support Palliat Care; 2017 Jun; 11(2):133-137. PubMed ID: 28333868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of retinoic acid and proteasome inhibitors for the treatment of leukemias is potentially dangerous.
    Wójcik C; Mlynarczuk I; Hoser G; Kawiak J; Stoklosa T; Gołab J; Wilk S
    Blood; 1999 Sep; 94(5):1827-8. PubMed ID: 10507840
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.